Michael J Metcalfe1, James E Ferguson1, Roger Li1, Lianchun Xiao2, Charles C Guo3, Bogdan A Czerniak3, Arlene Siefker-Radtke4, Shanna M Pretzsch1, Neema Navai1, David J McConkey5, Ashish M Kamat1, Mathew Campbell4, Colin Dinney6. 1. Departments of Urology at the University of Texas MD Anderson Cancer Center, Houston, Texas, USA. 2. Department of Biostatistics at the University of Texas MD Anderson Cancer Center, Houston, Texas, USA. 3. Department of Pathology at the University of Texas MD Anderson Cancer Center, Houston, Texas, USA. 4. Department of Genitourinary Medical Oncology at the University of Texas MD Anderson Cancer Center, Houston, Texas, USA. 5. Department of Urology at Johns Hopkins, Baltimore, Maryland, USA. 6. Departments of Urology at the University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Electronic address: cdinney@mdanderson.org.
Abstract
BACKGROUND: High-risk non-muscle-invasive bladder cancer (NMIBC) that invades into the lamina propria is frequently understaged and is associated with a risk of lymph node metastasis and death. OBJECTIVE: To identify high-risk features (HRFs) for NMIBC that may identify patients with poorer prognosis who may benefit from neoadjuvant chemotherapy (NAC) prior to radical cystectomy (RC). DESIGN, SETTING, AND PARTICIPANTS: We performed a single-center retrospective review of patients who underwent RC for NMIBC with invasion into the lamina propria between 1995 and 2013. HRFs included hydronephrosis, abnormal examination under anesthesia, lymphovascular invasion, or variant histology. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Pathology at RC, and overall (OS) and disease-specific (DSS) survival were evaluated and analyzed by Fisher's exact test, Student t test, Cox proportional hazards regression analysis, and the Kaplan-Meier method. RESULTS AND LIMITATIONS: We identified 336 patients with a median follow-up of 130 mo. Of these, 159 (47%) had no HRF, 140 (41.5%) had one HRF, and 37 (11%) had ≥2 HRFs. At RC, patients with ≥2 HRFs had a significantly higher rate of pathologic T stage upstaging and lymph node metastasis (p<0.05). Median OS was 139 mo for those with no HRF, 127 mo for those with one HRF, and 56 mo for those with ≥2 HRF (p=0.0057). HRFs are also associated with a decreased DSS (p=0.0009). Patients with ≥2 HRFs (11/37) who received NAC showed improved OS (21% vs 55% 5-yr OS, p=0.0353) and trended toward an improvement in DSS (25% vs 56% 5-yr OS, p=0.0716) compared with RC alone. CONCLUSIONS: The presence of ≥2 HRFs in NMIBC invading the lamina propria is associated with worse pathology at RC and a significant decrease in OS and DSS. NAC appears to provide benefit for these patients. Limitations include retrospective design and limited sample size. PATIENT SUMMARY: The presence of high-risk features in urothelial cancer with invasion into the lamina propria has a worse prognosis that may be mitigated by neoadjuvant chemotherapy.
BACKGROUND: High-risk non-muscle-invasive bladder cancer (NMIBC) that invades into the lamina propria is frequently understaged and is associated with a risk of lymph node metastasis and death. OBJECTIVE: To identify high-risk features (HRFs) for NMIBC that may identify patients with poorer prognosis who may benefit from neoadjuvant chemotherapy (NAC) prior to radical cystectomy (RC). DESIGN, SETTING, AND PARTICIPANTS: We performed a single-center retrospective review of patients who underwent RC for NMIBC with invasion into the lamina propria between 1995 and 2013. HRFs included hydronephrosis, abnormal examination under anesthesia, lymphovascular invasion, or variant histology. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Pathology at RC, and overall (OS) and disease-specific (DSS) survival were evaluated and analyzed by Fisher's exact test, Student t test, Cox proportional hazards regression analysis, and the Kaplan-Meier method. RESULTS AND LIMITATIONS: We identified 336 patients with a median follow-up of 130 mo. Of these, 159 (47%) had no HRF, 140 (41.5%) had one HRF, and 37 (11%) had ≥2 HRFs. At RC, patients with ≥2 HRFs had a significantly higher rate of pathologic T stage upstaging and lymph node metastasis (p<0.05). Median OS was 139 mo for those with no HRF, 127 mo for those with one HRF, and 56 mo for those with ≥2 HRF (p=0.0057). HRFs are also associated with a decreased DSS (p=0.0009). Patients with ≥2 HRFs (11/37) who received NAC showed improved OS (21% vs 55% 5-yr OS, p=0.0353) and trended toward an improvement in DSS (25% vs 56% 5-yr OS, p=0.0716) compared with RC alone. CONCLUSIONS: The presence of ≥2 HRFs in NMIBC invading the lamina propria is associated with worse pathology at RC and a significant decrease in OS and DSS. NAC appears to provide benefit for these patients. Limitations include retrospective design and limited sample size. PATIENT SUMMARY: The presence of high-risk features in urothelial cancer with invasion into the lamina propria has a worse prognosis that may be mitigated by neoadjuvant chemotherapy.
Authors: Wassim Kassouf; Samer L Traboulsi; Girish S Kulkarni; Rodney H Breau; Alexandre Zlotta; Andrew Fairey; Alan So; Louis Lacombe; Ricardo Rendon; Armen G Aprikian; D Robert Siemens; Jonathan I Izawa; Peter Black Journal: Can Urol Assoc J Date: 2015-10-13 Impact factor: 1.862
Authors: Venu Chalasani; Wassim Kassouf; Joseph L Chin; Yves Fradet; Armen G Aprikian; Adrian S Fairey; Eric Estey; Louis Lacombe; Ricardo Rendon; David Bell; Ilias Cagiannos; Darrell Drachenberg; Jean-Baptiste Lattouf; Jonathan I Izawa Journal: Can Urol Assoc J Date: 2011-04 Impact factor: 1.862
Authors: Marko Babjuk; Andreas Böhle; Maximilian Burger; Otakar Capoun; Daniel Cohen; Eva M Compérat; Virginia Hernández; Eero Kaasinen; Joan Palou; Morgan Rouprêt; Bas W G van Rhijn; Shahrokh F Shariat; Viktor Soukup; Richard J Sylvester; Richard Zigeuner Journal: Eur Urol Date: 2016-06-17 Impact factor: 20.096
Authors: Marco Moschini; Francesco Soria; Tobias Klatte; Gregory J Wirth; Mehmet Özsoy; Killian Gust; Alberto Briganti; Morgan Roupret; Martin Susani; Andrea Haitel; Shahrokh F Shariat Journal: Clin Genitourin Cancer Date: 2016-07-22 Impact factor: 2.872
Authors: Necole M Streeper; Christopher M Simons; Badrinath R Konety; DeSirae M Muirhead; Richard D Williams; Michael A O'Donnell; Fadi N Joudi Journal: BJU Int Date: 2008-10-06 Impact factor: 5.588
Authors: Daniel L Willis; Thomas W Flaig; Donna E Hansel; Matthew I Milowsky; Robert L Grubb; Hikmat A Al-Ahmadie; Elizabeth R Plimack; Theresa M Koppie; David J McConkey; Colin P Dinney; Vanessa A Hoffman; Michael J Droller; Edward Messing; Ashish M Kamat Journal: Urol Oncol Date: 2014-06-13 Impact factor: 3.498
Authors: Ashish M Kamat; Richard J Sylvester; Andreas Böhle; Joan Palou; Donald L Lamm; Maurizio Brausi; Mark Soloway; Raj Persad; Roger Buckley; Marc Colombel; J Alfred Witjes Journal: J Clin Oncol Date: 2016-01-25 Impact factor: 44.544
Authors: Mihaela Georgiana Musat; Christina Soeun Kwon; Elizabeth Masters; Slaven Sikirica; Debduth B Pijush; Anna Forsythe Journal: Clinicoecon Outcomes Res Date: 2022-01-10